Breaking News

Tweet TWEET

Lpath Announces Pricing of Public Offering of Common Stock

Lpath Announces Pricing of Public Offering of Common Stock 
SAN DIEGO, CA -- (Marketwire) -- 12/14/12 --  Lpath, Inc. (NASDAQ:
LPTN), today announced that it is selling 2,366,000 shares of its
common stock at a price to the public of $5.00 per share. The gross
proceeds from the sale of the shares, before deducting the
underwriting discount and estimated offering expenses payable by it,
are expected to be approximately $11.8 million. 
Lpath intends to use the net proceeds from this offering for research
and development activities, operating costs, capital expenditures and
for general corporate purposes, including working capital. Lpath may
also use a portion of the net proceeds to invest in or acquire
businesses or technologies that it believes are complementary to its
own, although Lpath has no current plans, commitments or agreements
with respect to any acquisitions as of the date of this press
release. Pending these uses, Lpath intends to invest the net proceeds
in investment grade, interest-bearing securities. 
Summer Street Research Partners is acting as the sole book-running
manager for this offering. Lpath has granted the underwriter a 45-day
option to purchase up to an aggregate of 354,900 additional shares of
common stock to cover over-allotments, if any. The offering is
expected to close on or about December 19, 2012, subject to the
satisfaction of customary closing conditions. 
A shelf registration statement on Form S-3 relating to the securities
described above has been declared effective by the Securities and
Exchange Commission ("SEC"). A preliminary prospectus supplement
relating to the offering has been filed with the SEC and is available
on the SEC's website located at www.sec.gov. Copies of the final
prospectus supplement relating to these securities, when available,
may be obtained from Summer Street Research Partners, Attention:
Prospectus Department, at 101 Arch Street, Boston, MA 02110, or via
telephone at (617) 532-6433, or via email at bryanm@ssrp.com. 
This press release does not and shall not constitute an offer to sell
or the solicitation of an offer to buy, nor will there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. 
About Lpath
 San Diego-based Lpath, Inc. is focused on developing
lipid-targeted therapeutics, an emerging field of medicine that
targets bioactive signaling lipids for the treatment of human
disease. The company has developed three drug candidates: iSONEP(TM)
is currently in a Phase 2 trial for wet AMD; ASONEP(TM) is scheduled
to begin a Phase 2 trial in Renal Cell Carcinoma patients; and
Lpathomab is a preclinical drug candidate.  
About Forward-Looking Statements
 The Company cautions you that the
statements included in this press release that are not a description
of historical facts are forward-looking statements. These include
statements regarding the Company's proposed public offering of its
common stock. Actual results may differ materially from those set
forth in this press release due to the risks and uncertainties
inherent in the Company's business, including, without limitation:
the results of the Company's pre-clinical testing and its clinical
trials may not support either further clinical development or the
commercialization of its drug candidates; the Company may not
successfully complete additional clinical trials for its product
candidates on a timely basis, or at all; the Company may fail to
obtain required governmental approvals for any its drug candidates;
the Company has a history of net losses and may never achieve or
maintain profitability; the Company may not be successful in
maintaining its commercial relationship with Pfizer Inc.; and the
Company may not be able to secure the funds necessary to support its
preclinical- and clinical-development plans. More detailed
information about the risk factors and uncertainties that may affect
the realization of forward-looking statements is set forth in the
Company's filings with the Securities and Exchange Commission (the
"SEC"), including its Annual Report on Form 10-K, its Quarterly
Reports on Form 10-Q and its other filings with the SEC. These
documents may be read free of charge on the SEC's website at
www.sec.gov. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
All forward-looking statements are qualified in their entirety by
this cautionary statement and the Company undertakes no obligation to
revise or update this press release to reflect events or
circumstances after the date hereof. This caution is made under the
safe harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995. 
Lpath, Inc.
Scott R. Pancoast
President & CEO
(858) 926-3200
spancoast@Lpath.com 
Lpath Investor Relations
Liolios Group, Inc.
(949) 574-3860
Ron Both: ron@liolios.com
Geoffrey Plank: geoffrey@liolios.com
lptn@liolios.com 
 
 
Press spacebar to pause and continue. Press esc to stop.